Roche files MabThera for early arthritis in EU
This article was originally published in Scrip
Executive Summary
Roche has filed its anti-CD20 monoclonal antibody MabThera (rituximab) with the EMEA to extend its label for rheumatoid arthritis (RA) to include patients who have not been treated with methotrexate; those who have had an inadequate response to methotrexate; and for the prevention of joint damage across the whole RA patient population.